Exergen Corporation has announced that two new studies from Postgraduate Medical Journal indicate that when used throughout a hospital, Exergen TemporalScanners deliver substantial cost savings while providing accuracy and ease of use, as supported by more than 70 peer-reviewed published studies for all ages and clinical settings.

10 Times Less Expensive Temporal Scanner

The first study, “Cost minimization analysis of thermometry in two different hospital systems [1] ,” was conducted at University Hospital Centre Zagreb (UHCZ) and University of Michigan Hospitals (UMH), each of which used the Exergen TAT-5000 to evaluate cost savings. Results dramatically favored TAT forehead thermometers over tympanic thermometry at UHCZ, where the cost of consumables per measurement would be more than 10 times cheaper for TAT, leading to considerable budget savings within a year of hospital-wide implementation. The UMH study concluded that routine use of Exergen TAT-5000 temporal thermometers would lead to cost savings over three years at UMH.

TAT-5000 Temporal Scanner

The second study, “Minimizing the costs of temperature monitoring in hospitals [2] ,” revealed that Exergen TAT-5000 savings exceeded $1.7 million when there were 10 beds per device used for five years. The study indicated that other forms of thermometry such as oral, axillary and rectal are not favored by hospital staff. This is due to numerous factors including time commitment needed from the healthcare provider, patient discomfort and the potential to wake a sleeping patient.

 

“We appreciate how cost is a critical consideration in hospital purchasing today, and we are committed to providing a product, the Exergen TAT-5000, that delivers significant cost savings,” said Francesco Pompei, Ph.D., CEO of Exergen Corporation. “This has wide implications for maximizing savings, as our thermometer is the single standard of uniform care in hospitals nationwide, giving more healthcare professionals and patients access to its many benefits.”

Exergen Temporal Scanner

The above, along with other independent studies, confirm suitability among all patient groups. These are including premature infants, adults and geriatrics, and under all medical conditions. For a complete list of studies visit www.exergen.com/c.